In the external dataset validation, compared with those in the normal control group, the expression levels of C1QC and CCL18 in the kidneys of type 2 diabetic nephropathy patients and in the subcutaneous or visceral fat of obese patients were upregulated, but the differences were not statistically significant. This evidence concerns the gene CCL18 and type 2 diabetes nephropathy.